

# J Andrew Livingston

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3035603/j-andrew-livingston-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46  
papers

555  
citations

12  
h-index

22  
g-index

49  
ext. papers

820  
ext. citations

5.1  
avg, IF

3.64  
L-index

#	Paper	IF	Citations
46	Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act. <i>Oncologist</i> , <b>2022</b> , 27, 135-143	5.7	0
45	Hypofractionated radiation therapy for unresectable or metastatic sarcoma lesions. <i>Advances in Radiation Oncology</i> , <b>2022</b> , 100913	3.3	0
44	Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association.. <i>Nature Communications</i> , <b>2022</b> , 13, 42	17.4	5
43	Factors impacting adolescent and young adult cancer patientsXdecision to pursue genetic counseling and testing.. <i>Supportive Care in Cancer</i> , <b>2022</b> , 1	3.9	0
42	Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis.. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2022</b> , OF1-OF9	4	1
41	Impact of Lagtime, Health Insurance Type, and Income Status at Diagnosis on the Long-Term Survival of Adolescent and Young Adult Cancer Patients. <i>Journal of Adolescent and Young Adult Oncology</i> , <b>2021</b> , 10, 164-174	2.2	4
40	Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS11575-TPS11575	2.2	1
39	Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskkeletal Ewing Sarcoma. <i>Oncologist</i> , <b>2021</b> , 26, 250-260	5.7	5
38	Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. <i>Cell Reports</i> , <b>2021</b> , 34, 108678	10.6	7
37	Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. <i>Cancer Gene Therapy</i> , <b>2021</b> , 28, 1325-1338	5.4	5
36	Impact of Race, Ethnicity, and Socioeconomic Status over Time on the Long-term Survival of Adolescent and Young Adult Hodgkin Lymphoma Survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 1717-1725	4	3
35	Young Adult Populations Face Yet Another Barrier to Care With Insurers: Limited Access to Proton Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 110, 1496-1504	4	1
34	Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors. <i>Cancer Epidemiology</i> , <b>2021</b> , 75, 102044	2.8	0
33	Long-term survival among 5-year survivors of adolescent and young adult cancer. <i>Cancer</i> , <b>2020</b> , 126, 3708-3718	6.4	13
32	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
31	Immuno-genomic landscape of osteosarcoma. <i>Nature Communications</i> , <b>2020</b> , 11, 1008	17.4	77
30	Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 812-822	8.7	4

29	A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 11509-11509	2.2	6
28	A phase I trial of aerosol gemcitabine for the treatment of patients with solid tumors and lung metastases.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS3645-TPS3645	2.2	0
27	PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. <i>Sarcoma</i> , <b>2020</b> , 2020, 8363986	3.1	5
26	Genomics and the Immune Landscape of Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , <b>2020</b> , 1258, 21-36	3.6	8
25	Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor. <i>Clinical Sarcoma Research</i> , <b>2020</b> , 10, 14	2.5	5
24	Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. <i>Cancers</i> , <b>2019</b> , 11,	6.6	7
23	MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. <i>Cancers</i> , <b>2019</b> , 11,	6.6	12
22	Short-Term Changes in Cardiac Function in Osteosarcoma Patients Receiving Anthracyclines. <i>Journal of Adolescent and Young Adult Oncology</i> , <b>2019</b> , 8, 385-386	2.2	2
21	Improving Outcomes for Adolescents and Young Adults With Sarcoma: A Focus on Cancer Care Delivery. <i>Journal of Oncology Practice</i> , <b>2019</b> , 15, 253-254	3.1	2
20	Pilot study of NKTR214 and nivolumab in patients with sarcomas.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 11010-11010	2.2	5
19	Extraskeletal Osteosarcomas: A Case Made for Combined Modality Local Therapy With Radiation and Surgery. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2019</b> , 42, 238-242	2.7	4
18	Extraskeletal Myxoid Chondrosarcomas: Combined Modality Therapy With Both Radiation and Surgery Improves Local Control. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2019</b> , 42, 744-748	2.7	9
17	Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2018</b> , 16, 66-97	7.3	121
16	Analysis of HSP27 and the Autophagy Marker LC3B Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 1315-1323	6.1	11
15	Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. <i>Current Oncology Reports</i> , <b>2018</b> , 20, 37	6.3	14
14	Emergency Department Visits by Adolescent and Young Adult Cancer Patients Compared with Pediatric Cancer Patients in the United States. <i>Journal of Adolescent and Young Adult Oncology</i> , <b>2018</b> , 7, 553-564	2.2	2
13	Disparities in Adolescent and Young Adult Sarcoma Survival: Analyses of the Texas Cancer Registry and the National SEER Data. <i>Journal of Adolescent and Young Adult Oncology</i> , <b>2018</b> , 7, 681-687	2.2	9
12	Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy. <i>Oncotarget</i> , <b>2018</b> , 9, 1602-1616 <sup>33</sup>		13

11	Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 10520-10520	2.2	
10	Genome and transcriptome profiling of relapsed and metastatic osteosarcoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 11522-11522	2.2	
9	Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. <i>Scientific Reports</i> , <b>2017</b> , 7, 11836	4.9	34
8	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. <i>Oncologist</i> , <b>2017</b> , 22, 1271-1277	5.7	16
7	Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. <i>Clinical Sarcoma Research</i> , <b>2017</b> , 7, 11	2.5	32
6	Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma. <i>Pediatric Blood and Cancer</i> , <b>2017</b> , 64, e26318	3	8
5	Chemotherapy for Bone Sarcoma in Adults. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, 208-16	3.1	30
4	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. <i>Oncotarget</i> , <b>2016</b> , 7, 64421-64430	3.3	12
3	Chemotherapy for bone sarcomas in adults: the MD anderson experience. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2015</b> , e656-60	7.1	11
2	3D tissue-engineered model of Ewing's sarcoma. <i>Advanced Drug Delivery Reviews</i> , <b>2014</b> , 79-80, 155-71	18.5	36
1	A computational network approach to identify predictive biomarkers and therapeutic combinations for anti-PD-1 immunotherapy in cancer		1